Sino Biopharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Sino Biopharmaceutical has a total shareholder equity of CN¥42.1B and total debt of CN¥9.5B, which brings its debt-to-equity ratio to 22.6%. Its total assets and total liabilities are CN¥66.7B and CN¥24.6B respectively. Sino Biopharmaceutical's EBIT is CN¥5.9B making its interest coverage ratio -22.2. It has cash and short-term investments of CN¥13.2B.
Key information
22.6%
Debt to equity ratio
CN¥9.51b
Debt
| Interest coverage ratio | -22.2x |
| Cash | CN¥13.18b |
| Equity | CN¥42.12b |
| Total liabilities | CN¥24.58b |
| Total assets | CN¥66.70b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SMZ1's short term assets (CN¥25.2B) exceed its short term liabilities (CN¥21.9B).
Long Term Liabilities: SMZ1's short term assets (CN¥25.2B) exceed its long term liabilities (CN¥2.6B).
Debt to Equity History and Analysis
Debt Level: SMZ1 has more cash than its total debt.
Reducing Debt: SMZ1's debt to equity ratio has increased from 8.2% to 22.6% over the past 5 years.
Debt Coverage: SMZ1's debt is well covered by operating cash flow (68.1%).
Interest Coverage: SMZ1 earns more interest than it pays, so coverage of interest payments is not a concern.